Get started
KALA BIO INC COM USD0.001 (POST REV SPLIT)KALA BIO INC COM USD0.001 (POST REV SPLIT)KALA BIO INC COM USD0.001 (POST REV SPLIT)

KALA BIO INC COM USD0.001 (POST REV SPLIT)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0JQ2 trade ideas

KALA New Drug on the Street Hi Traders We can't say much here! As always history has shown us when a new drug goes on the market we have 3 scenarios: 1 we're going up (green path) 2 the medicine is not good we are going down (red path) 3 we don't know what the medicine is like until many people take it let's go sideways (purple path) with all that is happening at the moment we are following the first scenario the probabilities looks good, but we will see as soon as the index open. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. don't forget to follow me for more news and updates. Thanks for reading!
NASDAQ:KALALong
by GP101
Kala Pharma 450% gain incomingBanks has a lot of Long Hedges Open on these tickers, they have been overall short the last 1,5 years. Now in March they began to close their first Long Hedge position. Question right now is, did they build up big position yet for the longside, or they just sold their long Hedge and want price to go down further. If we hold the lows of 0,59 here - no weekly close below and break the 0,93 lvl we should continue to the next Banks open Long Hedge at 2,66 from there on 1,68 should hold for price to continue to 4 $
NASDAQ:KALALong
by Henriman
2
KALA Levels + Short InfoShort squeeze stocks have become a favorite recently. KALA has started getting wrapped into the conversation. Looking at details from sites like FinViz, short float is around 20% meanwhile the float itself shows to be around 42 million shares. Plotting some levels, you'll notice that KALA is still in the lower channel on the fib retracement slowly heading toward the 786 area. However, before that happens, keep watch on an interim level around $3.40. It was previously a support level in July but seems to have become a resistance level as KALA was strongly rejected right at $3.40 on Friday. Aside from the technical/speculative trend, there are also a few things to watch with the company after a rough first half: " Kala specializes in eye treatments. Its EYSUVIS is quickly playing a leading role for the company. According to the company, this past quarter, it was a preferred prescription for short-term treatment of dry eye disease. Furthermore, Kala explained that its expanding market access with Commercial and Medicare Part D health plans...Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals, explained, “We are encouraged by the very positive feedback we consistently receive from physicians and patients, who describe EYSUVIS as an effective and comfortable medicine and look forward to building on this foundation as we continue with the EYSUVIS launch. In parallel, we continue to promote INVELTYS and are advancing our pipeline of new chemical entities for front and back of the eye diseases, as we work to build a robust and sustainable portfolio of innovative treatments.” " Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
NASDAQ:KALA
by PennyStocks101
recent higher lows illustrate sign of accumulationMost recent notes from BoA, "KALA provided updates on the preclinical programs, such as tyrosine kinase inhibitor program in retinal diseases (e.g. wet AMD), selective glucocorticoid receptor modulators (SEGRMs) and novel steroids. Mgmt. believes there is high unmet need in areas, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME) which require frequent administration and lead to poor compliance as a consequence. 1) the company continues to view payor access as an important factor in the success of the ongoing Eysuvis launch and is planning to provide updates on coverage on quarterly earnings calls. Management noted Eysuvis use will likely follow the payor mix of the DED market, which 50% of total Rx volume is currently commercial, 40% Medicare and the remaining 10% with a mix of cash and Medicaid. On out of pocket cost, copay is expected to be in the $25-$45 range at preferred tier and $50-$70 if not preferred. The company also has copay assistance cards in place to ease the potential hurdles to access with max. out of pocket cost of $40, and 2) its sales force of 91 reps is now in place with plans to expand to ~125 reps in 2021 pending visibility on COVID. Noting 80%+ of sales calls are in person, KALA is planning to ramp up its peer-to-peer programs in both virtual and live format. Recall our surveys of ophthalmologists (handling ~55% DED prescription) and optometrists (~45%) indicated the unmet need and demand for a short term DED relief option like Eysuvis.
NASDAQ:KALA
by KhanhC.Hoang
It's not too late to join the rally in KALA PHARMA, but not yet As earnings approach NASDAQ:KALA is taking a very bullish trajectory and seemingly some positioning is taking place. Currently the 200 &100 day MA's are converging and will hopefully avoid a bearish cross , if the price can break above we believe it to a good entry point. AVERAGE ANALYSTS PRICE TARGET $19.57 AVERAGE ANALYSTS RECOMMENDATION buy P/E RATIO SHORT INTEREST 7% COMPANY PROFILE Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Waltham, MA.
NASDAQ:KALALong
by RedHotStocks